TY  - GEN
AU  - Martinez-Useros, Javier
AU  - Rodriguez-Remirez, Maria
AU  - Borrero-Palacios, Aurea
AU  - Moreno, Irene
AU  - Cebrian, Arancha
AU  - Gomez del Pulgar, Teresa
AU  - del Puerto-Nevado, Laura
AU  - Vega-Bravo, Ricardo
AU  - Puime-Otin, Alberto
AU  - Perez, Nuria
AU  - Zazo, Sandra
AU  - Senin, Clara
AU  - Fernandez-Aceñero, Maria J
AU  - Soengas, MS
AU  - Rojo, Federico
AU  - Garcia-Foncillas, Jesus
PY  - 2014
UR  - https://hdl.handle.net/20.500.12105/25424
AB  - DEK is a transcription factor involved in stabilization of heterochromatin and cruciform structures. It plays an important role in development and progression of different types of cancer. This study aims to analyze the role of DEK in metastatic...
AB  - Baseline DEK expression was firstly quantified in 9 colorectal cell lines and normal mucosa by WB. SiRNA-mediated DEK inhibition was carried out for transient DEK silencing in DLD1 and SW620 to dissect its role in colorectal cancer aggressiveness....
AB  - The DEK oncogene is overexpressed in all colorectal cancer cell lines. Knock-down of DEK on DLD1 and SW620 cell lines decreased cell migration and increased irinotecan-induced apoptosis. In addition, low DEK expression level predicted irinotecan-based...
AB  - These data suggest DEK overexpression as a crucial event for the emergence of an aggressive phenotype in colorectal cancer and its potential role as biomarker for irinotecan response in those patients with KRAS wild-type status.
LA  - eng
PB  - BioMed Central (BMC)
KW  - DEK
KW  - Irinotecan
KW  - Aggressive phenotype
KW  - Metastatic colorectal cancer
KW  - KRAS
TI  - DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
TY  - research article
ER  -